Avène  ||| S:0 E:6 ||| NNP
Thermal  ||| S:6 E:14 ||| NNP
Spring  ||| S:14 E:21 ||| NNP
Water ||| S:21 E:26 ||| NNP
:  ||| S:26 E:28 ||| :
an  ||| S:28 E:31 ||| DT
active  ||| S:31 E:38 ||| JJ
component  ||| S:38 E:48 ||| NN
with  ||| S:48 E:53 ||| IN
specific  ||| S:53 E:62 ||| JJ
properties  ||| S:62 E:73 ||| NNS
Avène  ||| S:73 E:79 ||| NNP
Thermal  ||| S:79 E:87 ||| NNP
Spring  ||| S:87 E:94 ||| NNP
Water  ||| S:94 E:100 ||| NNP
( ||| S:100 E:101 ||| -LRB-
TSW ||| S:101 E:104 ||| NNP
)  ||| S:104 E:106 ||| -RRB-
is  ||| S:106 E:109 ||| VBZ
a  ||| S:109 E:111 ||| DT
natural  ||| S:111 E:119 ||| JJ
active  ||| S:119 E:126 ||| JJ
component  ||| S:126 E:136 ||| NN
characterized  ||| S:136 E:150 ||| VBN
by  ||| S:150 E:153 ||| IN
a  ||| S:153 E:155 ||| DT
low  ||| S:155 E:159 ||| JJ
mineral  ||| S:159 E:167 ||| NN
content ||| S:167 E:174 ||| NN
.  ||| S:174 E:176 ||| .
In  ||| S:176 E:179 ||| IN
vitro  ||| S:179 E:185 ||| JJ
experiments  ||| S:185 E:197 ||| NNS
have  ||| S:197 E:202 ||| VBP
demonstrated  ||| S:202 E:215 ||| VBN
the  ||| S:215 E:219 ||| DT
effect  ||| S:219 E:226 ||| NN
of  ||| S:226 E:229 ||| IN
Avène  ||| S:229 E:235 ||| NNP
TSW  ||| S:235 E:239 ||| NNP
on  ||| S:239 E:242 ||| IN
membrane  ||| S:242 E:251 ||| JJ
fluidity ||| S:251 E:259 ||| NN
,  ||| S:259 E:261 ||| ,
its  ||| S:261 E:265 ||| PRP$
antiradical  ||| S:265 E:277 ||| NN
and  ||| S:277 E:281 ||| CC
anti-inflammatory  ||| S:281 E:299 ||| JJ
properties ||| S:299 E:309 ||| NNS
,  ||| S:309 E:311 ||| ,
its  ||| S:311 E:315 ||| PRP$
effects  ||| S:315 E:323 ||| NNS
on  ||| S:323 E:326 ||| IN
many  ||| S:326 E:331 ||| JJ
mediators  ||| S:331 E:341 ||| NNS
involved  ||| S:341 E:350 ||| VBN
in  ||| S:350 E:353 ||| IN
the  ||| S:353 E:357 ||| DT
immune  ||| S:357 E:364 ||| JJ
response  ||| S:364 E:373 ||| NN
and  ||| S:373 E:377 ||| CC
its  ||| S:377 E:381 ||| PRP$
stimulating  ||| S:381 E:393 ||| JJ
effect  ||| S:393 E:400 ||| NN
on  ||| S:400 E:403 ||| IN
keratinocyte  ||| S:403 E:416 ||| JJ
differentiation ||| S:416 E:431 ||| NN
.  ||| S:431 E:433 ||| .
The  ||| S:433 E:437 ||| DT
clinical  ||| S:437 E:446 ||| JJ
efficacy  ||| S:446 E:455 ||| NN
of  ||| S:455 E:458 ||| IN
the  ||| S:458 E:462 ||| DT
water  ||| S:462 E:468 ||| NN
was  ||| S:468 E:472 ||| VBD
demonstrated  ||| S:472 E:485 ||| VBN
at  ||| S:485 E:488 ||| IN
the  ||| S:488 E:492 ||| DT
hydrotherapy  ||| S:492 E:505 ||| JJ
centre  ||| S:505 E:512 ||| NN
in  ||| S:512 E:515 ||| IN
chronic  ||| S:515 E:523 ||| JJ
and  ||| S:523 E:527 ||| CC
disabling  ||| S:527 E:537 ||| JJ
diseases  ||| S:537 E:546 ||| NNS
such  ||| S:546 E:551 ||| JJ
as  ||| S:551 E:554 ||| IN
atopic  ||| S:554 E:561 ||| JJ
dermatitis  ||| S:561 E:572 ||| NN
but  ||| S:572 E:576 ||| CC
also  ||| S:576 E:581 ||| RB
in  ||| S:581 E:584 ||| IN
various  ||| S:584 E:592 ||| JJ
settings  ||| S:592 E:601 ||| NNS
in  ||| S:601 E:604 ||| IN
medical  ||| S:604 E:612 ||| JJ
and  ||| S:612 E:616 ||| CC
post  ||| S:616 E:621 ||| VB
dermatology  ||| S:621 E:633 ||| JJ
procedure  ||| S:633 E:643 ||| NN
such  ||| S:643 E:648 ||| JJ
as  ||| S:648 E:651 ||| IN
photodynamic  ||| S:651 E:664 ||| JJ
therapy  ||| S:664 E:672 ||| NN
or  ||| S:672 E:675 ||| CC
photothermolysis ||| S:675 E:691 ||| NN
.  ||| S:691 E:693 ||| .
All  ||| S:693 E:697 ||| PDT
these  ||| S:697 E:703 ||| DT
data  ||| S:703 E:708 ||| NNS
support  ||| S:708 E:716 ||| VBP
the  ||| S:716 E:720 ||| DT
fact  ||| S:720 E:725 ||| NN
that  ||| S:725 E:730 ||| IN
the  ||| S:730 E:734 ||| DT
Avène  ||| S:734 E:740 ||| NNP
TSW  ||| S:740 E:744 ||| NNP
is  ||| S:744 E:747 ||| VBZ
an  ||| S:747 E:750 ||| DT
active  ||| S:750 E:757 ||| JJ
component ||| S:757 E:766 ||| NN
.  ||| S:766 E:768 ||| .
